Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

Abstract PET using 18 F-FDG for treatment monitoring in patients with lymphoma is one of
the most well-developed clinical applications. PET/CT is nowadays used during treatment to …

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …

Background We tested interim positron-emission tomography–computed tomography (PET-
CT) as a measure of early response to chemotherapy in order to guide treatment for patients …

Purpose Patients who receive combined modality treatment for stage I and II Hodgkin
lymphoma (HL) have an excellent outcome. Early response evaluation with positron …

Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated …

Purpose Recent advances in imaging, use of prognostic indices, and molecular profiling
techniques have the potential to improve disease characterization and outcomes in …

PURPOSE Nivolumab, an anti–programmed death-1 monoclonal antibody, has
demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin …

Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin …

Background Whether it is possible to reduce the intensity of treatment in early (stage I or II)
Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a …